FDA ODAC favors 2 CAR T-cell therapies for multiple myeloma
- A meeting of the United States FDA Oncologic Drugs Advisory Committee (ODAC) voted to expand the approval of Abecma and Carvykti, two types of chimeric antigen receptor (CAR) T-cell therapies, for multiple myeloma, allowing them to be used as an earlier line of defense. Abecma is already approved in the US as a treatment for patients with relapsed...
